ArticleSurgery today2026
Prior cholecystectomy may identify a biologically aggressive subset of RAS-mutated proximal colon cancer: A 13-year retrospective cohort study.
Article in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposesCholecystectomy (CCY) may influence the colorectal cancer (CRC) outcomes in a location-specific manner. We investigated the association between CCY history and RAS mutations in CRC, focusing on tumor location.
methodsWe retrospectively analyzed 1,340 patients with CRC diagnosed between 2012 and 2024, with an available RAS mutation status. Patients were classified into proximal and distal groups for analysis. The survival outcomes were compared using multivariate Cox proportional hazard regression models.
resultsCCY was associated with a higher RAS mutation prevalence in proximal CRC (58% vs. 48%) but a lower prevalence in distal CRC (30% vs. 44%). The coexistence of a history of CCY and RAS mutations was associated with worse OS in proximal CRC (p = 0.025), but not in distal CRC (p = 0.212). Among patients with proximal CRC, a multivariate analysis revealed that TNM stage III/IV (p < 0.001), non-resection initial strategy (p < 0.001), and coexistence of history of CCY and RAS mutation (p = 0.008) were independent predictors of poor OS.
conclusionsCCY had opposite effects on RAS mutation prevalence according to tumor location and, in combination with RAS mutation, identified a high-risk subgroup in proximal CRC. These findings suggest a location-specific phenomenon linking environmental changes to tumor biology. (192 words).
Indexed as
Identifiers
42566029What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.